天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

克唑替尼,Crizotinib

克唑替尼|T1661

價(jià)格 255 387 555
包裝 5mg 10mg 50mg
最小起訂量 1mg
發(fā)貨地 上海
更新日期 2024-12-02
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:克唑替尼英文名稱:Crizotinib
CAS:877399-52-5品牌: TargetMol
產(chǎn)地: 美國(guó)保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
純度規(guī)格: 99.87%產(chǎn)品類別: 抑制劑
貨號(hào): T1661
2024-12-02 克唑替尼 Crizotinib 5mg/255RMB;10mg/387RMB;50mg/555RMB 255 TargetMol 美國(guó) Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. 99.87% 抑制劑

Product Introduction

Bioactivity

名稱Crizotinib
描述Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor that inhibits c-MET and ALK receptors (IC50=8/20 nM), is ATP-competitive, and also inhibits ROS1. Crizotinib exhibits antitumor activity and inhibits tumor growth.
細(xì)胞實(shí)驗(yàn)Cells were seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media (with 0.04% BSA) after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors were added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells were washed once with HBSS supplemented with 1 mmol/L Na3VO4, and protein lysates were generated from cells. Subsequently, phosphorylation of selected protein kinases was assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates were (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase-conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethylbenzidine peroxidase substrate to initiate a colorimetric reaction that was stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer [1].
激酶實(shí)驗(yàn)c-Met catalytic activity was quantitated using a continuous-coupled spectrophotometric assay in which the time-dependent production of ADP by c-Met was determined by analysis of the rate of consumption of NADH. NADH consumption was measured by a decrease in absorbance at 340 nm by spectrophotometry at designated time points. To determine Ki values, PF-2341066 was introduced into test wells at various concentrations in the presence of assay reagents and incubated for 10 min at 37°C. The assay was initiated by the addition of the c-Met enzyme [1].
動(dòng)物實(shí)驗(yàn)Daily treatment with PF-2341066 given in water by oral gavage was initiated when tumors were 100 to 600 mm^3 in volume. Tumor volume was determined by measurement with electronic Vernier calipers, and tumor volume was calculated as the product of its length × width2 × 0.4. Tumor volume was expressed on indicated days as the median tumor volume ± SE indicated for groups of mice. Percent (%) inhibition values were measured on the final day of study for drug-treated compared with vehicle-treated mice and are calculated as 100 × {1?[(TreatedFinal day ? TreatedDay 1)/(ControlFinal day ? ControlDay 1)]}. Tumor regression values were determined by calculating the ratio of median tumor volumes at the time when treatment was initiated to the median tumor volume on the final day of study for a given treatment group. Significant differences between the treated versus the control groups (P ≤ 0.001) were determined using one-way ANOVA [1].
體外活性方法:HMVEC 內(nèi)皮細(xì)胞用 Crizotinib (0.083-1.33 μmol/L) 處理 7 天,使用顯微鏡觀察形態(tài)。 結(jié)果:Crizotinib 在纖維蛋白凝膠中抑制血清刺激的 HMVEC 分支小管形成。[1] 方法:9 種肺癌癥細(xì)胞用 Crizotinib 處理 72 h,使用 Cell Titer-Glo Luminescent Cell Viability Assay 檢測(cè)細(xì)胞活力。 結(jié)果:具有 MET 擴(kuò)增的兩種細(xì)胞系,EBC-1 和 H1993 均對(duì) Crizotinib 敏感,IC50 值≤10 nM。相反,Crizotinib 沒(méi)有顯著抑制具有 MET 突變 (H2122、H1437 和 H596)、具有 EGFR 突變 (PC9 和 HCC827) 或沒(méi)有這種基因擴(kuò)增或突變 (A549 和 H1299) 的癌癥細(xì)胞的增殖。[2]
體內(nèi)活性方法:為檢測(cè)體內(nèi)抗腫瘤活性,將 Crizotinib (3.125-50 mg/kg) 灌胃給藥給攜帶 GTL-16 異種移植物的 nu/nu 小鼠,每天一次,持續(xù)十一天。 結(jié)果:在 50 mg/kg/天的劑量水平下,100% 的腫瘤生長(zhǎng)抑制與持續(xù) 24 小時(shí)的 GTL-16 腫瘤中 c-Met 磷酸化的完全抑制相關(guān)。在 >50mg/kg/天的濃度水平下,未觀察到腫瘤生長(zhǎng)抑制的進(jìn)一步改善。[1]
存儲(chǔ)條件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 10 mg/mL (22.21 mM)
10% DMSO+90% Saline : 1 mg/mL (2.22 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
2eq.HCl : 45 mg/mL (100 mM)
關(guān)鍵字Cluster of differentiation 246 | c-Met/HGFR | PF02341066 | Inhibitor | ROS Kinase | Anaplastic lymphoma kinase | inhibit | CD246 | Autophagy | PF 02341066 | ALK tyrosine kinase receptor | Crizotinib | Anaplastic lymphoma kinase (ALK)
相關(guān)產(chǎn)品Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Hydroxychloroquine | Curcumin | Stavudine | Acetylcysteine | Paeonol | Sodium 4-phenylbutyrate
相關(guān)庫(kù)經(jīng)典已知活性庫(kù) | 抗癌活性化合物庫(kù) | 已知活性化合物庫(kù) | EMA 上市藥物庫(kù) | 激酶抑制劑庫(kù) | FDA 上市藥物庫(kù) | 酪氨酸激酶分子庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù)
關(guān)鍵字: 克唑替尼|||PF-02341066|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起,為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部,化學(xué)事業(yè)部,生物事業(yè)部和新材料部。 從虛擬篩選到實(shí)體化合物分子供應(yīng);從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成;從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選,從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化,我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。 經(jīng)過(guò)在中國(guó)市場(chǎng)五年的精心耕耘,我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商,為超過(guò)五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩
成立日期 2013-04-18 (12年) 注冊(cè)資本 566.2651萬(wàn)人民幣
員工人數(shù) 100-500人 年?duì)I業(yè)額 ¥ 1億以上
主營(yíng)行業(yè) 化學(xué)試劑,生物活性小分子 經(jīng)營(yíng)模式 貿(mào)易,試劑,定制,服務(wù)
  • TargetMol中國(guó)(陶術(shù)生物)
VIP 12年
  • 公司成立:12年
  • 注冊(cè)資本:566.2651萬(wàn)人民幣
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:小分子抑制劑,藥物篩選化合物庫(kù),天然產(chǎn)物,活性分子化合物等
  • 公司地址:上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓
詢盤

克唑替尼|T1661相關(guān)廠家報(bào)價(jià)

更多
產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
VIP9年
滄州恩科醫(yī)藥科技有限公司
2024-12-28
詢價(jià)
VIP6年
武漢弘德悅欣醫(yī)藥科技有限公司
2024-12-28
詢價(jià)
VIP1年
湖北鴻福達(dá)生物科技有限公司
2024-12-27
詢價(jià)
VIP6年
武漢裕清嘉衡藥業(yè)有限公司
2024-12-27
詢價(jià)
VIP3年
深圳藥緣研發(fā)中心有限公司
2024-12-27
詢價(jià)
VIP6年
上海澤葉生物科技有限公司
2024-12-27
詢價(jià)
VIP1年
濟(jì)南洣林醫(yī)藥技術(shù)有限公司
2024-12-27
¥100
VIP2年
蘇州海景醫(yī)藥科技有限公司
2024-12-27
¥230.00
VIP8年
上海博景化工有限公司
2024-12-27
詢價(jià)
VIP7年
武漢貝爾卡藥業(yè)有限公司
2024-12-26
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的